Abstract
Hepatitis B virus (HBV) infection is common (44%–80%) in injection drug users (IDUs),1–8 and younger IDUs are at high risk.9–11 Although a safe and effective vaccine is available, high vaccine completion rates in IDUs (70%–86%) have been achieved primarily in drug treatment settings.12–15 Among street-recruited young injectors in San Francisco, Calif, only 13% had serological evidence of prior immunization, and 28% had been infected with HBV.16 We combined cash incentives and street outreach with flexible immunization schedules to improve HBV vaccine completion in young injectors in San Francisco. We examined factors associated with vaccine completion and observed postvaccination antibody responses in completers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
